$LMAT News

5 Insightful Analyst Questions From LeMaitre’s Q1 Earnings Call

Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround

LeMaitre Vascular Inc (NASDAQ:LMAT): A Quality Investing Candidate Passing All Caviar Cruise Screen Tests

Insider Transaction: George LeMaitre Sells $5.03M Worth Of LeMaitre Vascular Shares

US$118 - That's What Analysts Think LeMaitre Vascular, Inc. (NASDAQ:LMAT) Is Worth After These Results

3 Reasons Growth Investors Will Love LeMaitre (LMAT)

LeMaitre (LMAT) Upgraded to Buy: Here's Why

Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $120

LeMaitre Vascular, Inc. Q1 2026 Earnings Call Summary

Citizens Maintains Market Outperform on LeMaitre Vascular, Raises Price Target to $127

Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Raises Price Target to $104

LeMaitre Vascular Q1 Earnings Call Highlights

LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript

LeMaitre Vascular (NASDAQ:LMAT) Reports Steady Q1 2026 Results with Earnings Beat and In-Line Revenue

LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates

LeMaitre (NASDAQ:LMAT) Posts Q1 CY2026 Sales In Line With Estimates

LeMaitre Q1 2026 Financial Results

LeMaitre Vascular Reports Q1 2026 Results: Full Earnings Call Transcript

LeMaitre Vascular Sees Q2 GAAP EPS $0.79-$0.84 vs $0.75 Est; Sees Sales $70.500M-$72.500M vs $71.105M Est

LeMaitre Vascular Raises FY2026 GAAP EPS Guidance from $2.81-$3.01 to $2.93-$3.08 vs $2.90 Est; Narrows FY2026 Sales Guidance from $276.000M-$284.000M to $277.000M-$283.000M vs $279.492M Est